Sg3 Management, LLC Alnylam Pharmaceuticals, Inc. Transaction History

Sg3 Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$159.56 - $209.29 $3.71 Million - $4.87 Million	-23,250 Reduced 57.76%	17,000 $2.88 Million
Q3 2021 Nov 15, 2021	BUY	$169.75 - $207.73 $5.98 Million - $7.32 Million	35,250 Added 705.0%	40,250 $7.6 Million
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $128,630 - $176,890	1,000 Added 25.0%	5,000 $848,000
Q1 2021 May 17, 2021	BUY	$126.83 - $175.69 $507,320 - $702,760	4,000 New	4,000 $565,000

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.